top of page

Publication (2017)

Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Ch.
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.

Clin Colorectal Cancer 2017; 16(2):e73-e88.

[Citation: 11 ] [IF: 3.86 (JCR 2017)]

​

Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP.
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Clin Cancer Res 2017; 23(10):2405-2413.

[Citation: 30] [IF: 10.20 (JCR 2017)]

​

Lam KO, Lee KC, Chiu J, Lee VH, Leung R, Choy TS, Yau T.
The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Postgrad Med J 2017; 93(1101):395-400.

[Citation: 14 ] [IF: 2.08 (JCR 2017)]

​

Ng L, Wan TM, Man JH, Chow AK, Iyer D, Chen G, Yau TC, Lo OS, Foo DC, Poon JT, Leung WK, Pang RW, Law WL.
Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer.
Oncotarget 2017; 8(16):27393-27400.

[Citation: 40 ] [IF: 5.17 (JCR 2016)]

​

El-Khoueiry AB*, Sangro B*,Yau T , Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THRd Meyer T, Kang YK, Yeo W, Chopra A,erson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. 
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
The Lancet 2017; 389(10088):2492-2502.

[Citation: 2062 ] [IF: 53.25 (JCR 2017)]

 

Miguel Martin , Frankie A HolmesBent EjlertsenSuzette Delaloge , Beverly MoyHiroji Iwata   , Gunter von Minckwitz , Stephen K L Chia  , Janine Mansi  , Carlos H Barrios  , Michael Gnant   , Zorica Tomašević   , Neelima Denduluri  , Robert Šeparović , Erhan Gokmen , Anna Bashford  , Manuel Ruiz Borrego , Sung-Bae Kim  , Erik Hugger Jakobsen  , Audrone Ciceniene  , Kenichi Inoue   , Friedrich Overkamp   , Joan B Heijns   , Anne C Armstrong  , John S Link  , Anil Abraham Joy  , Richard Bryce  , Alvin Wong  , Susan Moran  , Bin YaoFeng Xu  , Alan Auerbach  , Marc Buyse  , Arlene Chan  , ExteNET Study Group
Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. 
Lancet Oncology 2017 Dec;18(12):1688-1700

[Citation: 372 ] [IF: 36.42 (JCR 2017)]

​

Chiu JW, Kwok G, Yau T, Leung R.
Editorial to “Palbociclib and letrozole in advanced breast cancer”. 
Transl Cancer Res 2017; 6(0):S376-S379

[Citation: 3 ] [IF: 1.20 (JCR 2017)]
 

Kwok GW, Leung RC-Y, Chiu J, Tang V, Yau TC.
A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.

Journal of Clinical Oncology. 2017;35(15_suppl):e15049-e.

[Citation: - ] [IF: 26.36 (JCR 2017)]

bottom of page